Form 8-K RIGEL PHARMACEUTICALS For: Apr 16
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall St dips after AI-led selloff; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude hits more than five-month high on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- JetBlue shares fall amid American results, fuel cost concerns
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Nokia shares fall despite earnings beat on cash flow concerns
Rigel Pharmaceuticals regains rights as Lilly terminates license deal
April 21, 2026 4:22 PM EDTRigel Pharmaceuticals Inc. (NASDAQ: RIGL) received notice that Eli Lilly and Company will terminate their license and collaboration agreement, effective June 15, 2026, according to a company statement.
Lilly notified Rigel on April 16, 2026 of its decision to terminate the February 2021 agreement in its entirety. The... More



